Gradalis announces positive results from phase 2b VITAL trial of Vigil to treat patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer: Dallas Friday, January 16, ...

Survival rates in the United States are improving, a new report shows. In the annual report from the American ...

Suvemcitug combined with chemotherapy significantly improved PFS and OS in platinum-resistant recurrent ovarian cancer, nearly doubling median PFS and extending median OS. The trial demonstrated ...

Ohio has the 11th highest mortality rate for cancer, according to a recent American Cancer Society report. However, national ...